Business Description
ProQR Therapeutics NV
ISIN : NL0010872495
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.03 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.48 | |||||
Debt-to-EBITDA | -0.83 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.99 | |||||
Beneish M-Score | -4.99 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.8 | |||||
3-Year EPS without NRI Growth Rate | 26 | |||||
3-Year Book Growth Rate | -26.2 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.87 | |||||
9-Day RSI | 44 | |||||
14-Day RSI | 44.51 | |||||
6-1 Month Momentum % | 67.97 | |||||
12-1 Month Momentum % | 13.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.54 | |||||
Quick Ratio | 3.54 | |||||
Cash Ratio | 3.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.5 | |||||
Shareholder Yield % | 13.32 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -532.75 | |||||
Net Margin % | -429.75 | |||||
FCF Margin % | 309.75 | |||||
ROE % | -53.17 | |||||
ROA % | -18.63 | |||||
ROIC % | -73.97 | |||||
ROC (Joel Greenblatt) % | -161.6 | |||||
ROCE % | -21 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 6.71 | |||||
PS Ratio | 22.76 | |||||
PB Ratio | 3.57 | |||||
Price-to-Tangible-Book | 3.5 | |||||
Price-to-Free-Cash-Flow | 7.47 | |||||
Price-to-Operating-Cash-Flow | 6.97 | |||||
EV-to-EBIT | -1.89 | |||||
EV-to-EBITDA | -2.09 | |||||
EV-to-Revenue | 7.68 | |||||
EV-to-Forward-Revenue | 7.22 | |||||
EV-to-FCF | 2.53 | |||||
Price-to-Net-Current-Asset-Value | 6.07 | |||||
Price-to-Net-Cash | 6.51 | |||||
Earnings Yield (Greenblatt) % | -52.91 | |||||
FCF Yield % | 13.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ProQR Therapeutics NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 6.514 | ||
EPS (TTM) (€) | -0.35 | ||
Beta | 1.92 | ||
Volatility % | 62.12 | ||
14-Day RSI | 44.51 | ||
14-Day ATR (€) | 0.038904 | ||
20-Day SMA (€) | 1.849 | ||
12-1 Month Momentum % | 13.88 | ||
52-Week Range (€) | 1.065 - 2.564 | ||
Shares Outstanding (Mil) | 81.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ProQR Therapeutics NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ProQR Therapeutics NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ProQR Therapeutics NV Frequently Asked Questions
What is ProQR Therapeutics NV(FRA:0PQ)'s stock price today?
When is next earnings date of ProQR Therapeutics NV(FRA:0PQ)?
Does ProQR Therapeutics NV(FRA:0PQ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |